Document is current
Any future updates will be listed below
-
Authors
Lin, Nan
Damask, Amy
Boyapati, Anita
Hamilton, Jennifer D.
Hamon, Sara
Ternes, Nils
Nivens, Michael C.
Penn, John
Lopez, Alexander
Reid, Jeffrey G. https://orcid.org/0000-0001-8645-4713
Overton, John
Shuldiner, Alan R.
Abecasis, Goncalo https://orcid.org/0000-0003-1509-1825
Baras, Aris https://orcid.org/0000-0002-6830-3396
Paulding, Charles https://orcid.org/0000-0002-7918-3561
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi Genzyme
- License Information
-
More Information
Article History
Received: 26 February 2020
Revised: 16 December 2021
Accepted: 24 January 2022
First Online: 11 February 2022
Competing interests
: NL, AD, A Boyapati, JDH, SH, MCN, AL, JGR, JO, ARS, GA, A Baras, and CP are employees of Regeneron Pharmaceuticals, Inc., and may hold stock and/or stock options in the company. JP is a former employee of Regeneron Pharmaceuticals, Inc., and may hold stock and/or stock options in the company, and is currently employed by DNAnexus. NT is an employee of Sanofi and may hold stock and/or stock options in the company.
